Healthcare ❯ Pharmaceuticals ❯ Drug Development

Clinical Trials

Regulatory Approval FDA Approval Obesity Treatments Lenacapavir Nanobody Technology Zaltenibart Weight-loss Drugs Weight Loss Drugs FDA Approvals Prostate Cancer Treatments

Bepirovirsen Induces Functional Cure in About One in Five Hepatitis B Patients

Regulators are reviewing bepirovirsen following trial data that show it lowers viral RNA along with the hepatitis B surface antigen.

Regeneron Slides as Melanoma Combo Fails to Beat Keytruda in Phase 3

Cormedix Lifts 2026 Outlook After Q1 Beat, Sets H2 FDA Filing Plan for Rizzeo

Isomorphic Labs Raises $2.1 Billion to Scale AI Drug Design

Milestone Posts Q1 Loss as CARDAMYST Launch Shows Early Uptake and AFib-RVR Phase 3 Begins

Capricor Outlines Daramyocell’s FDA Review and Launch Prep as Distributor Dispute Looms

Analysts Lift Eli Lilly Targets After Blowout Quarter and Foundayo Debut

AstraZeneca Tops Q1 Forecasts, Reaffirms 2026 Outlook as Oncology Fuels Growth

AbbVie Tops Q1 and Raises 2026 Outlook as Skyrizi and Rinvoq Offset Humira Decline

Sagimet Prices $175 Million Stock Offering as It Plans U.S. Phase 3 Acne Trial

FDA Approves First Glucocorticoid Receptor Blocker for Platinum-Resistant Ovarian Cancer

Biomea Fusion Reports Positive 52-Week Phase II Results for Icovamenib in Diabetes

Most Weight Lost on GLP-1 Drugs Returns After Stopping, New Analysis Finds

Zealand Plunges as Roche Obesity Drug Posts 10.7% Weight Loss With Placebo‑Like Tolerability

Can-Fite's Namodenoson Clears Phase IIa Safety Bar in Pancreatic Cancer

CHMP Backs Xolremdi for WHIM Syndrome Under Exceptional Circumstances

Ironwood Sees LINZESS Above $1.1 Billion in 2026 as FDA-Aligned STARS II Nears Launch

Geron Guides 2026 Rytelo Sales to $220–$240 Million After $184 Million Debut Year

Bayer Sues J&J Over Erleada Marketing, Alleging False Superiority Claims Versus Nubeqa

Viking Therapeutics' Obesity Drug Moves Into Phase 3 as Investors Weigh Upside